Stephanie Graff, Director of Breast Oncology at Brown University Health, shared a post on X:
“PHILA study 1L HER2+ MBC
Demonstrates Pyrotinib and HT (trastuzumab/docetaxel) improves PFS, OS compared to HT
PFS: median 22.1 vs. 10.5 months; HR 0.44
OS: HR 0.64; 1-sided P=0.0038; 4-year OS rate 74.5% vs. 64.3%
Important global data.”
More posts featuring Stephanie Graff.
Read the post “Highlights from Day 1 of SABCS 2024” on oncodaily.com.
Stephanie Graff is the Director of Breast Oncology at Brown University Health and an Associate Professor of Medicine at Brown University’s Legorreta Cancer Center.
She also serves as the Director of Breast Oncology at Lifespan and is a Medical Advisor for the Dr. Susan Love Foundation for Breast Cancer Research.She is an Associate Editor of Cancer Medicine, and chairs the editorial board of Oncology Times.
